医学
哮喘
变应原免疫治疗
免疫球蛋白E
免疫学
疾病
过敏
保健品
皮肤病科
过敏原
内科学
抗体
病理
作者
Angela Klain,Cristiana Indolfi,Giulio Dinardo,Fabio Decimo,Maria Angela Tosca,Michele Miraglia Del Giudice,Giorgio Ciprandi
标识
DOI:10.1080/1744666x.2022.2093188
摘要
Pollen-induced allergic rhinitis (PIAR) is a widespread disease in children, and its prevalence is rapidly evolving. In addition, it may be associated with other atopic diseases, in particular asthma. In most cases, PIAR can be treated effectively by avoiding exposure to responsible allergens and using symptomatic treatments, including intranasal/oral antihistamines or/and nasal corticosteroids, according to ARIA guidelines. In recent decades, new medicines have been studied and developed: allergen-specific immunotherapy (AIT), anti-IgE antibodies, and probiotics. In addition, nutraceuticals have also been used as add-on treatments. This review aims to discuss and compare the old and new therapeutic strategies for PIAR in children.Allergic rhinitis is a type 2 inflammatory disease. The management of patients with PIAR entails medications, AIT, and ancillary therapies. In addition, children with PIAR and associated severe asthma may be inclusively treated with biologics. Namely, subjects with allergic comorbidities could benefit from biological agents. However, AIT presently remains the unique causal treatment for PIAR.New strategies may include combined treatments, mainly concerning fixed associations with antihistamines and corticosteroids, nutraceutical products, and new AIT formulations.
科研通智能强力驱动
Strongly Powered by AbleSci AI